The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On April 16, Merck reduced its acquisition offer for Terns Pharmaceuticals by $1 billion to a total of $6.7 billion. The per-share offer was lowered from $61 to $53 following a review of cancer drug trial data.